Integrated Model for the Prevention of Anal Cancer using screen and Treat for HSIL (IMPACT)

使用 HSIL 筛查和治疗预防肛门癌的综合模型 (IMPACT)

基本信息

  • 批准号:
    10540829
  • 负责人:
  • 金额:
    $ 77.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-15 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

Project Abstract Anal cancer risk is 80-fold higher among men who have sex with men (MSM) living with HIV compared to the general population, making MSM a critical population for implementing evidence-based anal cancer prevention interventions. A randomized controlled trial at 21 clinical sites in the United States of people living with HIV, recently established treatment of high-grade squamous intraepithelial lesions (HSIL) as an evidence-based intervention (EBI) for anal cancer prevention. Given its established efficacy, HSIL screening and treatment should be implemented as prophylactic care to prevent anal cancer in low- and middle-income country (LMIC) settings where HIV is highly prevalent. To accelerate adoption of HSIL screening and treatment in LMIC settings, we will leverage an existing HIV infrastructure, the TRUST clinic, an MSM-friendly facility in Nigeria that has been providing HIV care to a cohort of MSM since 2012. We conducted a proof-of-concept anal cancer screening and treatment study at the TRUST clinic and found high uptake in the MSM community; representativeness, as those screened had similar prevalence of HIV and high-risk human papillomavirus as our overall cohort; and overall patient satisfaction. Despite high screening volumes, we under-detected and under-treated HSIL. Knowledge gaps in HSIL screening and treatment among both the care team and the participants were identified as major barriers that impeded implementation of the EBI with fidelity. The objective of the proposed Integrated Model for the Prevention of Anal Cancer using screen and Treat for HSIL (IMPACT) study is to address these barriers while capitalizing on facilitators within the existing TRUST clinic infrastructure to create an enhanced training on Screening and Treatment of HSIL (e-STH) intervention. To achieve this goal, in AIM 1, we will use the Consolidated Framework for Implementation Research (CFIR) and mixed methods to identify barriers and facilitators to usual training on the EBI at the TRUST clinic. In AIM 2, we will engage an implementation team to co-design the e-STH intervention by matching the barriers identified with CFIR with specific strategies in the Expert Recommendations for Implementing Change (ERIC) framework. We will then take an iterative improvement approach to test and refine the implementation of the e-STH intervention based on specific outcomes. In AIM 3, we will conduct a prospective study to evaluate the reach, efficacy, and implementation and explore the sustainability of e-STH compared to usual training using the RE-AIM framework. The proposed IMPACT study will provide insight into implementation of an HSIL screening and treatment EBI adapted for existing community-based HIV clinics in Nigeria and generate essential evidence for scalability across LMICs.
项目摘要 与艾滋病毒感染者相比,与艾滋病毒感染者发生性关系的男性(MSM)患肛门癌的风险高出80倍。 一般人群,使MSM成为实施循证肛门癌预防的关键人群 干预措施。一项在美国21个临床地点对艾滋病毒感染者进行的随机对照试验, 最近建立的治疗高度鳞状上皮内病变(HSIL)作为一种循证医学 干预(EBI)预防肛门癌。鉴于其既定的疗效,HSIL筛查和治疗 在低收入和中等收入国家(LMIC)应作为预防肛门癌预防性护理来实施 艾滋病毒高度流行的地方。为了加快在LMIC环境中采用HSIL筛查和治疗, 我们将利用现有的艾滋病毒基础设施,即TRUST诊所,这是尼日利亚的一个适合男同性恋者的设施,该设施拥有 自2012年以来一直为一群男男性行为者提供艾滋病毒护理。我们进行了一个概念验证的肛门癌筛查 在TRUST诊所进行的一项治疗研究中发现,MSM群体的吸收率很高;代表性, 接受筛查的人群与我们的整体队列人群的HIV和高危人乳头瘤病毒患病率相似; 患者总体满意度。尽管筛查量很高,但我们对HSIL的检测和治疗不足。 护理团队和参与者在HSIL筛查和治疗方面的知识差距被确定 这是阻碍忠实地实施EBI的主要障碍。拟议综合方案的目标 使用筛查和治疗HSIL预防肛门癌的模型(IMPACT)研究旨在解决这些问题 障碍,同时利用现有TRUST诊所基础设施内的促进者, HSIL筛查和治疗(e-STH)干预培训。为了实现这一目标,在AIM 1中,我们将使用 实施研究综合框架和确定障碍的混合方法, 协助者在TRUST诊所接受关于EBI的常规培训。在AIM 2中,我们将聘请一个实施团队, 共同设计e-STH干预措施,将CFIR确定的障碍与 实施变革的专家建议(ERIC)框架。然后我们将进行迭代 改进方法,以测试和完善电子STH干预措施的实施, 结果。在AIM 3中,我们将进行一项前瞻性研究,以评估范围、有效性和实施情况, 探索e-STH与使用RE-AIM框架的常规培训相比的可持续性。拟议 IMPACT研究将提供对HSIL筛查和治疗EBI实施的深入了解, 在尼日利亚现有的基于社区的艾滋病毒诊所中进行评估,并为整个中低收入国家的可扩展性提供必要的证据。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sylvia Adebajo其他文献

Sylvia Adebajo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sylvia Adebajo', 18)}}的其他基金

Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center
使用证据对性和性别少数青少年进行弹性艾滋病毒实施科学 (RISE) 临床研究中心
  • 批准号:
    10749084
  • 财政年份:
    2023
  • 资助金额:
    $ 77.32万
  • 项目类别:
Integrated Model for the Prevention of Anal Cancer using screen and Treat for HSIL (IMPACT)
使用 HSIL 筛查和治疗预防肛门癌的综合模型 (IMPACT)
  • 批准号:
    10705313
  • 财政年份:
    2022
  • 资助金额:
    $ 77.32万
  • 项目类别:

相似海外基金

I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 77.32万
  • 项目类别:
    Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 77.32万
  • 项目类别:
    Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 77.32万
  • 项目类别:
    Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 77.32万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 77.32万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 77.32万
  • 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 77.32万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 77.32万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 77.32万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 77.32万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了